The stem cell sector is fueled by innovation and rapid change. To keep you up-to-date, we recently released new coverage of the industry. Check it out and let us know what you think! [Read more…]
What Types of Mesenchymal Stem Cell (MSC) Research Are Getting Funded?
To analyze trends within the mesenchymal stem cell (MSC) industry, it is valuable to consider grant rate data. Previously, the U.S. federal government operated an online tool called CRISP (“Computer Retrieval of Information on Scientific Projects”). It was a searchable database of federally funded biomedical research projects conducted at universities, hospitals, and other U.S. research institutions. The database allowed users to search the CRISP interface for grants funding for specific types of scientific research, using text-based search terms.
However, that has since been replaced by RePORTer (Research Portfolio Online Reporting Tools)1, a more powerful database and search tool supported by the U.S. Department of Health and Human Services. RePORTer allows users to search a comprehensive repository of National Institutes of Health (NIH) funded research projects resulting from NIH funding. [Read more…]
Regenestem to Bring Regenerative Medicine to Cuba Following First Visit by an American President in 88 Years
In a historic event this week, Barack Obama became the first American president to visit Cuba in 88 years. The three-day visit was the result of a December 2014 agreement between President Obama and Cuban President Raul Castro to “end an estrangement that began when Cuba’s revolution ousted a pro-American government in 1959.”
Since President Obama announced the beginning of normalization between the U.S. and Cuba, channels are now being opened and opportunities created among businesses and other organizations to access and share information across many fields. As an American company Regenestem, LLC (http://www.regenestem.com) will bring the field of regenerative medicine to the island of Cuba later this year for valuable information sharing at an international level.
Regenestem, a medical practice company focused on adult stem cell therapies and physician training with particular growth in Latin America, is presenting an innovative conference in Cuba devoted to regenerative medicine, in association with the Cuban Institute of Hematology. [Read more…]
No Longer Just for Humans — Cord Blood Banking Now Available to Horses Too
VetiCell, LLC, has announced that it is launching a proactive stem cell storage program for animals, in which it will collect stem cells from the umbilical cord of horses or from the reproductive tissues of dogs following spay or neuter.
VetiCell is a sister company to AlphaCord, a human cord blood bank, with the two companies having the same owner and staff.
Currently, there are a couple companies operating in the veterinary stem cell market that collect stem cells through invasive methods (adipose or bone marrow). However, VetiCell’s new model is to collect veterinary stem cells without surgery from the umbilical cord of horses or from reproductive tissues after canine spay and neuter. These methods require no additional invasive surgery to collect an animal’s stem cells.
Since 2006, BioInformant has been tracking the human stem cell banking market. Initially, the market was focused on the storage of umbilical cord blood, although it has expanded over the past ten years to include the storage of other types of stem cells, including those present within cord tissue, dental pulp, adipose tissue, and more.
With hundreds of human cord blood banks now competing worldwide, it will be interesting to see whether any of them add equine cord blood banking to their portfolio of human stem cell storage services.
Current Bottlenecks in MSC Research: Widespread MSC Misconceptions
This is a guest post from RoosterBio, written by Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.
We blogged several months ago about bottlenecks in the bioprocessing of Mesenchymal Stem Cells that are impeding their clinical translation. While the development of robust and scalable manufacturing methods, reduced cost of goods, and implementation of solid Quality Systems are all necessary for increased clinical use of MSCs, there are also current misconceptions surrounding MSCs, rooted in decades-old science, that are holding the field back. [Read more…]
- « Previous Page
- 1
- …
- 150
- 151
- 152
- 153
- 154
- …
- 194
- Next Page »